Download PDF
Thromb Haemost 2009; 101(02): 340-344
DOI: 10.1160/TH08-09-0582
Platelets and Blood Cells
Schattauer GmbH

Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention

Gabriele Busch
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Birgit Steppich
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Dirk Sibbing
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Siegmund-Lorenz Braun
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Andreas Stein
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Philipp Groha
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Albert Schömig
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Adnan Kastrati
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Nicolas von Beckerath
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
,
Ilka Ott
1   Deutsches Herzzentrum und 1. Medizinische Klinik der Technischen Universität Muenchen, Munich, Germany
› Author Affiliations
Further Information

Publication History

Received: 08 September 2008

Accepted after major revision: 04 January 2008

Publication Date:
23 November 2017 (online)

    Permissions and Reprints

Summary

lating platelets and CD11b, CD14 and CD15 on circulating leukocytes were evaluated by flow cytometry. Cytokine levels of IL-12p70, tumour necrosis factor (TNF), IL-8, IL-6, IL-1β and IL-10 were determined by cytometric bead array. Platelet surface expression of PAC-1, P-Selectin and GPIbα was significantly reduced after PCI in patients receiving bivalirudin as compared to heparin. Similarly, CD11b expression on CD14+ monocytes was diminished after bivalirudin. However, no differences were observed in cytokine levels between the bivalirudin and the heparin group, before or after PCI. In conclusion, our data suggest that bivalirudin may reduce platelet and monocyte activation in patients undergoing elective PCI. Thereby, bivalirudin might reduce periinterventional thrombotic complications.

Keywords

Antithrombin - platelet pharmacology - leukocyte function/ activation
 

  • References

  • 1 McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci 2003; 93: 381-396.
    CrossrefPubMedGoogle Scholar
  • 2 Smith Jr SC, Feldman TE, Hirshfeld Jr JW. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.
    CrossrefPubMedGoogle Scholar
  • 3 Lincoff AM, Kleiman NS, Kereiakes DJ. et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. J Am Med Assoc 2004; 292: 696-703.
    CrossrefPubMedGoogle Scholar
  • 4 Lincoff AM, Bittl JA, Harrington RA. et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Med Assoc 2003; 289: 853-863.
    CrossrefPubMedGoogle Scholar
  • 5 Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.
    CrossrefPubMedGoogle Scholar
  • 6 Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 2002; 13: 161-165.
    CrossrefPubMedGoogle Scholar
  • 7 Keating FK, Dauerman HL, Whitaker DA. et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005; 16: 401-405.
    CrossrefPubMedGoogle Scholar
  • 8 Chen MS, Lincoff AM. Direct thrombin inhibitors. Curr Cardiol Rep 2005; 7: 255-259.
    CrossrefPubMedGoogle Scholar
  • 9 Busch G, Seitz I, Steppich B. et al. Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005; 25: 461-466.
    PubMedGoogle Scholar
  • 10 Di Cera E. Thrombin interactions. Chest 2003; 124: 11S-17S.
    CrossrefPubMedGoogle Scholar
  • 11 Sibbing D, Busch G, Braun S. et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008; 29: 1504-1509.
    CrossrefPubMedGoogle Scholar
  • 12 Anand SX, Kim MC, Kamran M. et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007; 100: 417-424.
    CrossrefPubMedGoogle Scholar
  • 13 Ott I, Neumann FJ, Gawaz M. et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996; 94: 1239-1246.
    CrossrefPubMedGoogle Scholar
  • 14 Kastrati A, Neumann FJ, Mehilli J. et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696.
    CrossrefPubMedGoogle Scholar